Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBTNASDAQ:BRNSNASDAQ:INKTNASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$3.14$3.69$2.11▼$12.60$5.95M0.03473,898 shs7,175 shsBRNSBarinthus Biotherapeutics$0.98-1.6%$0.86$0.64▼$1.99$39.69M-0.7836,775 shs35,961 shsINKTMiNK Therapeutics$7.59+0.1%$7.48$4.56▼$13.79$30.25M0.1512,097 shs2,010 shsKALAKALA BIO$4.38-7.6%$3.69$2.92▼$11.20$28.26M-1.9895,037 shs61,807 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare-3.68%-10.29%-19.28%-35.66%-55.45%BRNSBarinthus Biotherapeutics+0.97%-7.41%+15.34%-6.54%-47.37%INKTMiNK Therapeutics+0.99%+2.95%+4.41%-8.02%-22.90%KALAKALA BIO+15.33%+15.89%+38.60%-31.80%-23.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare2.0533 of 5 stars0.05.00.04.32.71.70.0BRNSBarinthus Biotherapeutics3.353 of 5 stars3.55.00.00.02.70.81.3INKTMiNK Therapeutics2.7919 of 5 stars3.54.00.00.02.11.70.6KALAKALA BIO3.8594 of 5 stars3.53.00.04.41.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/ABRNSBarinthus Biotherapeutics 3.00Buy$5.17425.07% UpsideINKTMiNK Therapeutics 3.00Buy$37.50394.07% UpsideKALAKALA BIO 3.00Buy$13.50208.22% UpsideCurrent Analyst Ratings BreakdownLatest ALBT, INKT, BRNS, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.004/4/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/24/2025BRNSBarinthus BiotherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/21/2025BRNSBarinthus BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/18/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.37M4.35N/AN/A($17.22) per share-0.18BRNSBarinthus Biotherapeutics$14.97M2.65N/AN/A$4.85 per share0.20INKTMiNK TherapeuticsN/AN/AN/AN/A($5.23) per shareN/AKALAKALA BIO$3.89M7.26N/AN/A$2.79 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$16.71M-$19.96N/A∞N/A-1,125.59%N/A-73.69%8/18/2025 (Estimated)BRNSBarinthus Biotherapeutics-$73.35M-$1.64N/AN/AN/AN/A-34.26%-29.30%8/6/2025 (Estimated)INKTMiNK Therapeutics-$22.46M-$2.52N/AN/AN/AN/AN/A-189.14%8/12/2025 (Estimated)KALAKALA BIO-$42.20M-$8.24N/AN/AN/AN/A-448.61%-69.37%8/5/2025 (Estimated)Latest ALBT, INKT, BRNS, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A5/13/2025Q1 2025ALBTAvalon GloboCareN/A-$1.43N/A-$1.43N/AN/A5/7/2025Q1 2025BRNSBarinthus Biotherapeutics-$0.34-$0.49-$0.15-$0.49N/AN/A3/28/2025Q4 2024KALAKALA BIO-$2.28-$1.74+$0.54-$1.74N/AN/A3/20/2025Q4 2024BRNSBarinthus Biotherapeutics-$0.50-$0.51-$0.01-$0.51N/A$14.97 million3/18/2025Q4 2024INKTMiNK Therapeutics-$0.50-$0.62-$0.12-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.110.11BRNSBarinthus BiotherapeuticsN/A8.938.93INKTMiNK TherapeuticsN/A0.890.89KALAKALA BIO3.182.152.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%BRNSBarinthus Biotherapeutics25.20%INKTMiNK Therapeutics2.87%KALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%BRNSBarinthus Biotherapeutics10.70%INKTMiNK Therapeutics22.48%KALAKALA BIO8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare51.89 million686,000Not OptionableBRNSBarinthus Biotherapeutics10740.34 million37.01 millionN/AINKTMiNK Therapeutics303.99 million3.15 millionNo DataKALAKALA BIO306.45 million5.58 millionNot OptionableALBT, INKT, BRNS, and KALA HeadlinesRecent News About These CompaniesMary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) StockJune 5, 2025 | insidertrades.comKALA BIO (NASDAQ:KALA) Earns "Outperform" Rating from OppenheimerJune 3, 2025 | americanbankingnews.comKALA BIO to Present at Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comKALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | finance.yahoo.comChief Minister cancels programme over unauthorised nature of venueApril 20, 2025 | thehindu.comKALA BIO: Q4 Earnings SnapshotMarch 31, 2025 | timesunion.comKALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | markets.businessinsider.comKALA BIO to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comKala Bio announces CEO departure, appoints interim leaderFebruary 13, 2025 | msn.comKALA BIO, Inc.: KALA BIO Announces Chief Executive Officer TransitionFebruary 12, 2025 | finanznachrichten.deKala Bio appoints new interim CEO amid leadership shuffleFebruary 12, 2025 | msn.comKala announces resignation of CEO Iwicki, Bazemore appointed interim CEOFebruary 12, 2025 | markets.businessinsider.comKala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An OverreactionFebruary 12, 2025 | msn.comKALA BIO Announces Chief Executive Officer TransitionFebruary 12, 2025 | globenewswire.comKALA stock soars to 52-week high, reaching $8.81January 29, 2025 | msn.comKala Pharmaceuticals files to sell 1.67M shares of common stock for holdersJanuary 24, 2025 | markets.businessinsider.comKALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in StockJanuary 8, 2025 | insidertrades.comBros. Advisors Lp Baker Purchases 310,559 Shares of KALA BIO, Inc. (NASDAQ:KALA) StockJanuary 1, 2025 | insidertrades.comKALA BIO, Inc. Secures $10.75 Million in Private Placement to Advance Clinical Development of KPI-012December 30, 2024 | quiverquant.comKALA BIO Announces $10,750,000 Private PlacementDecember 30, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALBT, INKT, BRNS, and KALA Company DescriptionsAvalon GloboCare NASDAQ:ALBT$3.14 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$3.28 +0.15 (+4.62%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Barinthus Biotherapeutics NASDAQ:BRNS$0.98 -0.02 (-1.60%) Closing price 03:58 PM EasternExtended Trading$1.03 +0.05 (+5.18%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.MiNK Therapeutics NASDAQ:INKT$7.59 +0.01 (+0.13%) Closing price 04:00 PM EasternExtended Trading$7.60 +0.01 (+0.12%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.KALA BIO NASDAQ:KALA$4.38 -0.36 (-7.59%) Closing price 04:00 PM EasternExtended Trading$4.66 +0.28 (+6.39%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Will Warner Bros. Discovery’s Split Produce Double the Upside? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
